الفهرس 
coverOnly 14 pages are availabe for public view
 |  | from | 147 |  |  |
| | | from | 147 | | |
Abstract
Chronic adult periodontitis is a bacterially induced chronic
inflammatory disease that destroys the connective tissue and bone that
support teeth. P. gingivalis and P. intermedia are among the strongest
markers of periodontal destruction, through their high virulence factor
and overcoming cellular and humoral defense mechanisms. Because of
high pathogenesis of these bacteria, the dental practitioner needs the
antibiotic in addition to surgical and/ or nonsurgical therapy in treatment
of severe chronic periodontitis in which P.g and P.i are involved.
Moxifloxacin is a fourth-generation synthetic fluoroquinolone
antibacterial agent. It is marketed worldwide (as the hydrochloride) under
the brand names Avelox, Avalox, and Avelon for oral treatment. It is a
broad-spectrum antibiotic that is active against both Gram-positive and
Gram-negative bacteria and a good activity against periodontal
pathogens.
Accordingly; the aim of the present study was to assess the clinical
and microbiological effects of moxifloxacin as an adjunct to scaling /root
planing and to compare it to scaling/ root planing alone and scaling/ root
planing combined with the established antibiotic regimen metronidazole
and augmentin in patients with advanced chronic periodontitis.
Thirty patients with advanced chronic periodontitis were used in the
current study and divided into three groups; the 1
st
group included ten
patients treated with scaling and root planing (SRP) alone (control
group), ten patients were treated with SRP plus Augmentin(625mg, every
8 hours for 10 days) and metronidazole (250 mg, every 8 hours for 10
days), and the last ten patients treated with SRP plus moxifloxacin
(400mg, once daily for 10 days) (test group).
In each subject, subgingival plaque samples were collected from The
4 deepest sites of 4 teeth, one in each quadrant at baseline before initial
therapy and 3 and 6 months after the completion of therapy for evaluation
of their content of two subgingival microbial species including P.i and
P.g using the DNA probes.
The result of quantitative PCR technique revealed, after 3 months
and after 6 months, there was no statistically significant difference
between Moxifloxacin and Augmentin/Metronidazole groups; both
showed the statistically significant highest mean percentage reduction in
log10 values of P. gingivalis as (after 3 months MXF 43.5%, Aug/MET
45.6% and after 6 months MXF 32.2%, Aug/MET 34.4%). While SRP
without antibiotic showed the statistically significant lowest mean
percentage reduction in log10 values of P. gingivalis as (after 3 months
30.5% and after 6 months 21.4%). Similarly after 3 months and after 6
months, there was no statistically significant difference between
Moxifloxacin and Augmentin/ Metronidazole; both showed the
statistically significant highest mean percentage reduction in log10 values
of P. intermedia as (after 3 months MXF 42.2%, Aug/MET 50.8% and
after 6 months MXF 37.9%, Aug/MET 38.7%). SRP without antibiotic
showed the statistically significant lowest mean percentage reduction in
log10 values of P. intermedia as (after 3 months 19.7%, after 6 months
12.8%).
The results obtained suggested that moxifloxacin as an adjunct to SRP
represents a viable approach to treat severe chronic periodontitis.